Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.61 |
| ▸ | GABRD | O14764 | 2/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.61 |
| ▸ | GABRE | P78334 | 2/20 | 0.61 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.61 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.61 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.61 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7020108 | 0.98 | GABRP (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5151271 | 0.85 | TSHR (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10123136 | 0.84 | TSHR (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2500952 | 0.82 | TSHR (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30452033 | 0.82 | TSHR (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15120986 | 0.81 | TSHR (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL17873669 | 0.81 | TSHR (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL990694 | 0.81 | TSHR (0.64) | P4HTMTSHRSMN1; SMN2LMNA | |
| SCHEMBL24589251 | 0.79 | TSHR (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7886665 | 0.79 | ALDH1A1 (0.52) | TSHRSMN1; SMN2ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103145707-B | The preparation method of hydrogenated pyridine [4,3-b] Benzazole compounds | Institute of Toxicology and Drugs, Chinese Academy of Military Medical Sciences (CN) | 2016-05-25 | — | — | CN | claimed |
| EP-2581374-B1 | Preparation of tetrahydropyrido[4,3-b]indole derivatives | INST PHARM & TOXICOLOGY AMMS (CN) | 2014-03-19 | — | — | EP | claimed |
| EP-2581374-A1 | Preparation of tetrahydropyrido[4,3-b]indole derivatives | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2013-04-17 | — | — | EP | claimed |
| US-20120122914-A1 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCE P.L.A.CHINA (CN) | 2012-05-17 | — | — | US | claimed |
| CN-102395369-A | Sustained-release composition containing tetrahydropyridine [4,3-b ] indole derivative and preparation method of derivative | INST PHARM & TOXICOLOGY AMMS | 2012-03-28 | — | — | CN | claimed |
| EP-2417973-A1 | SUSTAINED RELEASE COMPOSITION CONTAINING TETRAHYDROPYRIDO Ý4, 3-b¨INDOLE DERIVATIVE AND PREPARATION METHOD OF DERIVATIVE | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. (CN) | 2012-02-15 | — | — | EP | claimed |
| US-12600719-B2 | Salt inducible kinase inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4660192-A1 | SALT INDUCIBLE KINASE INHIBITORS | The General Hospital Corporation (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-1168667-A | Pyridopyrimidones, quinolines and fused N-heretocycles as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-12-24 | — | — | CN | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
| EP-0466115-B1 | Microbiological oxidation of ethyl groups in heterocycles | LONZA AG (CH) | 1995-05-10 | — | — | EP | disclosed |
| US-5242816-A | Production of carboxylic acids, pseudomonas | LONZA LTD. (CH) | 1993-09-07 | — | — | US | disclosed |
| EP-0466115-A1 | Microbiological oxidation of ethyl groups in heterocycles | LONZA AG (CH) | 1992-01-15 | — | — | EP | disclosed |
| US-3935193-A | ANTIBIOTICS | TOYO JOZO KABUSHIKI KAISHA (JA) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | GABRP 2624/4885GABRD 2321/4885GABRA1 3032/4885 |
| US-12600719-B2 | Salt inducible kinase inhibitors | GRK6, SGK1, CSNK1A1 | GABRP 1926/4885GABRD 2510/4885GABRA1 2275/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | GABRP 2624/4885GABRD 2321/4885GABRA1 3032/4885 |
| US-20120122914-A1 | Sustained-release composition containing tetrahydropyrido[4,3-b]indole derivatives and preparation of the derivatives | HTT, HTR5A, HTR3B | GABRP 1172/4885GABRD 3561/4885GABRA1 3125/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | GABRP 4368/4885GABRD 4740/4885GABRA1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.